Loading...
Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis EGFR T790M-C797S in NSCLC: A Case Report
The emergence of epidermal growth factor receptor (EGFR) exon 20 p.C797S is one of the major resistance mechanisms for osimertinib. However, there are no standard of care for non-small cell lung cancer (NSCLC) patients after acquiring EGFR C797S currently, which brings significant challenges to post...
Na minha lista:
| Udgivet i: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8093742/ https://ncbi.nlm.nih.gov/pubmed/33958875 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S298655 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|